[April 29, 2016]

Global Pulmonary Arterial Hypertension Pipeline Report H1 2016 - Review of 38 Companies & Drug Profiles - Research and Markets

Research and Markets has announced the addition of the "Pulmonary Arterial Hypertension - Pipeline Review, H1 2016" report to their offering.

This report provides comprehensive information on the therapeutic development for Pulmonary Arterial Hypertension, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Pulmonary Arterial Hypertension and special features on late-stage and discontinued projects.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Key Topics Covered:

1. Introduction
2. Pulmonary Arterial Hypertension Overview
3. Therapeutics Development
4. Pipeline Products for Pulmonary Arterial Hypertension - Overview
5. Pipeline Products for Pulmonry Arterial Hypertension - Comparative Analysis
6. Pulmonary Arterial Hypertension - Therapeutics under Development by Companies
7. Pulmonary Arterial Hypertension - Therapeutics under Investigation by Universities/Institutes
8. Pulmonary Arterial Hypertension Products Glance
9. Late Stage Products
10. Clinical Stage Products
11. Early Stage Products
12. Pulmonary Arterial Hypertension - Products under Development by Companies
13. Pulmonary Arterial Hypertension - Products under Investigation by Universities/Institutes
14. Pulmonary Arterial Hypertension - Companies Involved in Therapeutics Development

• APT (News - Alert) Therapeutics, Inc.
• Arena Pharmaceuticals, Inc.
• Asahi Kasei Pharma Corp.
• Ascendis Pharma A/S
• Bial - Portela & Ca, S.A.
• Bristol-Myers Squibb Company
• Carolus Therapeutics, Inc.
• Celsion Corporation
• Complexa, Inc.
• Corridor Pharmaceuticals Inc.
• Cytokinetics, Inc.
• Eli Lilly and Company
• F. Hoffmann-La Roche Ltd.
• Gilead Sciences, Inc.
• Insmed Incorporated
• INVENT Pharmaceuticals, Inc.
• Johnson & Johnson
• Kowa Company, Ltd.
• Mallinckrodt Plc
• Mezzion Pharma Co. Ltd.
• miRagen Therapeutics, Inc.
• Morphogen-IX Limited
• Nippon Kayaku Co., Ltd.
• Nippon Shinyaku Co., Ltd.
• Novartis AG
• Pluristem Therapeutics Inc.
• Proteo, Inc.
• Pulmokine, Inc.
• Reata Pharmaceuticals, Inc.
• Respira Therapeutics, Inc.
• Selten Pharma, Inc
• Silence Therapeutics Plc
• SteadyMed Therapeutics, Inc.
• Suda Ltd
• Toray Industries, Inc.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160429005791/en/

[ Back To TMCnet.com's Homepage ]